Robert Feldman, MD
Interventional Cardiology · Ocala, FLNPI 1346345550
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $8,800 of the $14,226 with a category attached, or 61.9%. Boston Scientific accounts for 82.0% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2019 at $6,356 and has fallen 93.8% since, to $396 in 2025.
Across 81 payments — averaging $175.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$12K
- Medtronic$788
- Abiomed$407
- Teleflex LLC$301
- Edwards Lifesciences$210
- Endologix LLC$180
- plus $673 from 12 others
Across 143 payments — averaging $1226.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Surmodics, Inc.$85K
- Abbott$35K
- Cardiovascular Systems Inc.$31K
- Boston Scientific$18K
- AstraZeneca$7K
What the payments were for
- Consulting fees$8,80062%
- Travel & lodging$1,95714%
- Food & beverage$3,40624%
- Education$350%
- Other$280%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 22 | $11,666 |
| Medtronic(2 entities) | 19 | $788 |
| Abiomed | 3 | $407 |
| Teleflex LLC | 2 | $301 |
| Edwards Lifesciences | 2 | $210 |
| Endologix LLC | 2 | $180 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 13 | $141 |
| Inari Medical, Inc. | 2 | $116 |
| Johnson & Johnson | 1 | $98 |
| Penumbra, Inc. | 6 | $88 |
| Abbott | 2 | $69 |
| W. L. Gore & Associates, Inc. | 1 | $35 |
| Baxter Healthcare | 1 | $28 |
| Recor Medical Inc | 1 | $25 |
| Innovation Technologies Inc | 1 | $22 |
| Cardiva Medical, Inc. | 1 | $19 |
| Cook Medical LLC | 1 | $18 |
| Alydia Health | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,226 in reported general payments places this provider in the 65th percentile of 623 interventional cardiology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ClopidogrelClopidogrel Bisulfate | 274 | $3,267 |
| Atorvastatin Calcium | 40 | $378 |
| Prednisone | 16 | $16 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Ocala
- Gregory VonmeringOcala$61K
- Arthur LeeGainesville$1.8M
- Santhosh MathewsBradenton$1.4M
- Siddharth WayangankarJacksonville$1.2M
- Patrick CambierTrinity$901K
- Zahid AminOrlando$635K
- Rohit AminPensacola$560K
- Eduardo de MarchenaMiami$498K
- Dominick AngiolilloJacksonville$387K
- Miguel DiazHialeah$383K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.